Purpose Panobinostat, a pan-deacetylase inhibitor, increases acetylation of proteins associated with growth and survival of malignant cells. This phase 2 study evaluated the efficacy of intravenous (IV) panobinostat in patients with castration-resistant prostate cancer (CRPC) who had previously received chemotherapy. The primary end point was 24-week progression-free survival. Secondary end points included safety, tolerability, and the proportion of patients with a prostate-specific antigen (PSA) decline.
Introduction
Prostate cancer is driven by progressive genetic and epigenetic aberrations. Emerging data strongly indicate that the entire epigenome is dysregulated during prostate cancer development, therefore representing a target for therapeutic intervention [1] .
Several lines of evidence have demonstrated the importance of deacetylases (DACs) in the progression of prostate cancer [2] [3] [4] [5] . The presence of overexpressed histone deacetylases (HDACs), particularly the class 1 isoforms, has been documented in tumor samples and associated with poor patient outcomes after radical prostatectomy [6] [7] [8] . Experimental data have suggested that castration-resistant prostate cancer (CRPC) could respond to agents inhibiting heat shock protein 90 (HSP90), a molecular chaperone regulated by HDAC6 [9] , because the activity of several HSP90 client proteinsincluding androgen receptor (AR)-remains crucial for disease progression [10, 11] .
It is demonstrated that the importance of deacetylase inhibitors (DACis) has been noted to have greater antiproliferative effects on AR-positive prostate cancer cells than on their AR-negative counterparts and inhibit tumor growth in both castration-sensitive and castration-resistant xenograft models [12, 13] . In addition to targeting HDAC6-which affects AR stability via HSP90 hyperacetylation-direct suppression of AR transcription and modulation of the acetylation of nonhistone proteins, such as the transcription factors E2F1 and p53, have been implicated in DACi's complex mode of action in experimental models [14] [15] [16] . In light of their high potency to inhibit tumor cell growth in vivo, several DACis have entered clinical development [17] .
Panobinostat is a novel pan-DACi that demonstrates potent inhibition of a broad range of histone and nonhistone DACs, leading to acetylation of intracellular targets involved in oncogenesis such as p53, hypoxia-inducible factor-1a, a-tubulin, and HSP90 [17, 18] . In a study by Liu et al. [19] , panobinostat was able to revert the resistance of androgen-independent (AI) LNCaP cells to bicalutamide and apoptosis. Single-agent panobinostat was also found to block AR activity in CRPC models [14] , and to have antitumor activity in combination with docetaxel in AR-positive AI xenografts [20] .
Initial clinical development of panobinostat included both oral and intravenous (IV) formulations in solid tumors and hematologic malignancies [18] . Oral panobinostat (20 mg) showed minimal clinical activity in CRPC, whereas the combination of the same schedule of oral panobinostat (15 mg) given 3 times weekly with standard docetaxel resulted in a C50 % reduction in prostatespecific antigen (PSA) in five of eight (63 %) CRPC patients, including two patients who achieved a partial response by modified Response Evaluation Criteria In Solid Tumors (RECIST) [21] [22] [23] . These studies, along with preclinical data suggesting a dose-dependent effect of panobinostat on PSA expression [14] , led to the decision to expand the clinical investigation of CRPC to the IV formulation, which demonstrated higher peak concentrations ([20-to 30-fold) and exposures (area under the curve 3.5-59) than the oral formulation [24] . This decision was supported by the initial evidence of clinical activity in a patient with Gleason grade 9, stage IV CRPC treated with single-agent IV panobinostat 20 mg/m 2 in a phase 1 trial. Therefore, the development of panobinostat in CRPC was continued with this phase 2 trial exploring single-agent IV panobinostat in patients previously treated with chemotherapy.
Patients and methods

Study design
This open-label, single-arm, multicenter phase 2 study evaluated the efficacy and safety of single-agent IV panobinostat in patients with CRPC. The primary end point was rate of progression-free survival (PFS) at 24 weeks using modified RECIST criteria [22, 25] . Secondary end points included safety, tolerability, overall survival (OS), tumor response, duration of stable disease, and PSA response per Prostate-Specific Antigen Working Group (PSAWG) 1999 Guidelines [26] . This study adhered to the Declaration of Helsinki and the International Conference on Harmonisation ICH Harmonised Tripartite Guidelines for Good Clinical Practice. Approval was obtained from each independent ethics committee and local institutional review board, and all patients provided written informed consent. This study is registered in www.clinicaltrials.gov as NCT00667862.
Patient selection
Adult patients with metastatic CRPC that progressed on or after one or two cytotoxic therapies with evidence of progressive disease (PD)-defined as C2 new lesions on a bone scan and/or per RECIST criteria-were eligible for this study [22, 25] . Patients with two consecutive increases in PSA over a previous reference value per PSAWG guidelines, an Eastern Cooperative Oncology Group performance status of B1, and normal laboratory tests were eligible. Patients without surgical castration required a serum testosterone level \50 ng/mL with continuation of luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy. Medically castrated patients willing to continue LHRH agonist/antagonist therapy during study treatment were eligible. Patients who received prior first-line antiandrogen therapy or responded to second-line therapy had to have had PD documented by rising PSA levels after 4-6 weeks. Treatment discontinuation from flutamide (C4 weeks), bicalutamide, megestrol acetate, cyproterone acetate, or nilutamide (C6 weeks) prior to study enrollment was required. Patients with active central nervous system disease, impaired cardiac function, liver or renal disease, history of invasive malignancies, peripheral neuropathy, and/or Common Terminology Criteria for Adverse Events (version 3) grade C2 diarrhea were not eligible. Prior treatment-related exclusion criteria included chemotherapy or bisphosphonates B4 weeks prior to study; immunotherapy B2 weeks prior to study; prior DACi treatment for prostate cancer; and concomitant use of valproic acid, medications that may prolong the QT interval or induce torsade de pointes, and CYP3A4/5 inhibitors or inducers.
Treatment plan
Patients received 20 mg/m 2 panobinostat (IV infusion over 30 min) on days 1 and 8 of a 21-day cycle. Patients remained on treatment until PD, intolerable toxicity, start of new cancer therapy, withdrawal of consent, or death. Dose adjustments and interruptions were permitted, but patients could not receive doses \10 mg/m 2 . A maximum 4-week break in the treatment for toxicity resolution was permitted. Patients could be considered for dose re-escalation if they met protocol-specified criteria for C3 weeks at the lower dose.
Duration of therapy, monitoring, and response assessment
Patients were monitored by history and physical examination, toxicity assessment, and PSA level every 3 weeks. Laboratory evaluations included coagulation, urinalysis, and thyroid function tests once per cycle; hematology and biochemistry once per week; blood and urine for bone markers once per cycle after cycle 2; electrocardiogram (ECG) on days 1 and 8 of cycle 1; and serum testosterone every 3 months. Response assessment by bone and computed tomography (CT) scans and/or other appropriate imaging was performed every 12 weeks. Patients were removed from the protocol if there was evidence of PD by PSA or RECIST criteria or symptomatic PD [25] . Patients with PD by bone scan only at first assessment continued treatment, with reassessment after 6 additional weeks of therapy. Patients with documented PD at C24 weeks were considered as having PD not requiring confirmation. Patients were followed for survival until the protocol was amended to remove the collection of this parameter due to the lack of clinical activity.
Definition of response and progression
Disease progression in the study was defined by one or more of the following criteria: PSA progression (50 % increase from nadir and an absolute increase in PSA by 2 ng/mL maintained for C3 weeks); measurable disease progression (progression of target lesions) and nonmeasurable lesion progression (worsening of bone scan defined by development of C2 new lesions confirmed on a second scan at least 6 weeks later); appearance of new metastatic lesions outside the bone; or unequivocal progression of existing nontarget lesions [25] .
Objective responses were defined using RECIST criteria [25] . PSA response was defined based on the PSAWG 1999 guidelines [26] . Bone disease was evaluated by bone scan, with disease characterized as complete response if there was disappearance of all osseous lesions; stable or improved if there were no new lesions and/or no new or worsening pain; and progression if there was the appearance of C2 new skeletal lesions. An increase in the size or intensity of lesions was not considered progression.
End points and statistical design
The primary objective of this trial was to evaluate the activity of panobinostat, with the primary end point defined as the proportion of patients who did not demonstrate PD or death at 24 weeks. Panobinostat was considered inactive if the PFS rate was B10 % and active if the PFS rate was C30 %, based on the published analyses in this disease setting [22, 27, 28] . Given the late time point for measuring progression, a single-stage design was used. A sample size of 35 patients achieved 90 % power to detect the 20 % difference in PFS rate at a 5 % significance level using a v 2 test. Kaplan-Meier method was to be used to estimate median PFS and OS and 95 % confidence intervals. Data from participating centers were combined and analyzed as a single treatment group using SAS Ò version 9.2
Results
Patient population
A total of 35 patients were enrolled in this study. Median age was 67 years (range 51-85 years; Table 1 ), with 11 patients (31.4 %) C75 years of age. All 35 patients had a history of several lines of prior antiandrogen therapy, including bicalutamide (97.1 %), and at least one cytotoxic therapy, including docetaxel (88.6 %). In the majority of patients (80.0 %), baseline disease progression was assessed by PSA level, but progression was also determined by measurable disease and bone scan in 37.1 and 34.3 % of patients, respectively.
Patient disposition
Of the 35 patients enrolled in the study, 34 (97.1 %) were taken off the study; 29 (85.3 %) of these were due to Cancer Chemother Pharmacol (2013) 72:537-544 539 disease progression (Fig. 1 ). There were three deaths (8.6 %) on study, none of which were suspected to be treatment related. Mean duration of exposure to panobinostat was 59 days (median 49 days; range 7-175 days). Eighteen patients (51.4 %) received B2 cycles (&6 weeks) of therapy, of whom eight (44.4 %) had PD and six (33.3 %) had toxicity. For the remaining four patients, early withdrawal of consent (n = 3, 16.7 %) and death (n = 1, 5.6 %) were the reasons for ending the study treatment. An additional 13 (37.1 %) patients received between two and four cycles, while four patients (11.4 %) received more than four cycles (range 5-9 cycles). All four of these patients were taken off the study due to PD; one patient had to stop the study drug after eight treatment cycles due to grade 3 thrombocytopenia and neutropenia.
Efficacy and response
In the 35 treated patients, there were no documented objective responses. PSA was assessed in 34 patients ( Table 2 ; Fig. 2 ), of whom only five (14.7 %) had a decline from baseline during treatment, none reaching a decrease of 50 % or more. Of the five patients with a decline in serum PSA, four had a\30 % decrease in PSA: one after two cycles, two after three cycles, and one after five cycles of treatment. One patient with a [30 % decrease in PSA completed nine cycles. One patient had carcinoembryonic antigen as the only marker of his prostate cancer, which declined by 43 % after one treatment; however, he discontinued panobinostat due to the recurrence of baseline atrial fibrillation with a rapid ventricular response. PD or death was reported for 28 patients (80.0 %) within 24 weeks from the start of the study treatment. All of these patients had PD with an increase in PSA, and the majority (71.4 %) also showed radiological PD with bone and/or soft tissue disease. At the end of 24 weeks, only four (11.4 %) patients were alive without PD. Table 3 ). The most frequent AEs with a suspected drug relationship included fatigue (19 patients, 54.3 %), thrombocytopenia (19 patients, 54.3 %), and nausea (17 patients, 48.6 %). Serious AEs were reported in 14 patients (40.0 %) and were considered drug related in seven (20.0 %) patients. As shown in Table 4 , QTcF prolongation between 30 and 60 ms was the most frequent QT abnormality (11 patients, 31.4 %). Postbaseline QTcF [ 480 ms was observed in four patients (11.4 %), with only one patient experiencing a QTcF increase [500 ms. Other common ECG abnormalities included asymptomatic changes in T-wave morphology (flat, inverted, and biphasic) and depressed ST segment.
Discussion
Recent phase 3 data for enzalutamide and abiraterone confirm the central role of the AR and AR signaling in the progression of prostate cancer throughout the spectrum of the disease [29, 30] . The role of epigenetic changes in regulating AR overexpression in CRPC remains to be further explored, and despite the lack of activity of oral vorinostat [31] and oral panobinostat [21] as monotherapy in the clinic, DACi has a strong scientific rationale for use in CRPC [32] . Since preclinical models demonstrated a dose-dependent effect of DACi on PSA expression [14] and IV panobinostat demonstrated much greater exposure compared with the oral formulation [24] , the decision was made to evaluate the IV formulation of panobinostat at the recommended phase 2 dose (20 mg/ m 2 ) for patients with CRPC who had previously received docetaxel. Unchanged from baseline, n (%) All 1 (2.9)
Best change from baseline defined as (lowest postbaselinebaseline)/baseline PSA prostate-specific antigen a Thirty-four of 35 patients were followed for PSA. One patient was followed for carcinoembryonic antigen However, despite preclinical promise, the PFS rate at 24 weeks did not indicate a sufficient level of clinical activity, and no patients showed a PSA decrease of C50 % qualifying as a protocol-defined response. All patients experienced toxicities, with most (71.4 %) having at least one grade 3 AE. Grade 4 thrombocytopenia developed in four patients (11.4 %) . Analysis of scheduled ECGs revealed QTcF prolongation, a known yet manageable DACi class effect [33] . Maximum postbaseline QTcF of [480 to B500 ms was reported in three (8.6 %) patients, with one experiencing QTcF [ 500 ms. No clinical sequelae were associated with these episodes of QTcF prolongation. Overall, treatment with panobinostat was not associated with new or unexpected AEs indicative of a specific risk in this population, but the lack of efficacy and the observed rate of grade 3-4 AEs did not justify further study in this population.
The mechanisms of DACi are complex, and methods of administration such as dose level and schedule are likely to influence intratumoral growth in ways that may not be apparent from standard imaging techniques (CT, bone scan) and PSA responses. To date, analysis of clinical activity of DACi has been limited to PSA response and histone acetylation in mononuclear cells, which may not accurately reflect the activity of these agents. Although histone acetylation in mononuclear cells occurs at very low doses of these agents, it is not a surrogate for the effects on the tumor itself and does not correlate with clinical response [31] . Furthermore, intermittent low doses of oral panobinostat in patients with CRPC failed to demonstrate clinical activity and were associated with a more rapid post-therapy rise in PSA [21] , suggesting a possible stimulatory effect of low doses of panobinostat as seen in preclinical models [14] .
Given the toxicity seen in this and other DACi trials, it is possible that suboptimal cell inhibitory plasma concentrations of DACi can explain why there was less clinical activity than expected. In our study, 42.9 % of patients required some adjustment in dose, potentially limiting the therapeutic efficacy of the drug. This underscores the importance of correlative studies within trials such as these to help determine the pharmacodynamic effects of the drug. It is unclear whether the dose and schedule were suboptimal or whether the drug itself was inactive against CRPC, thus raising the question of whether a different formulation and/or dose schedule would be effective in this patient population. At present, open questions remain regarding the optimal design of future studies for this class of agents in prostate cancer. These questions include the search for biomarkers predictive of clinical outcome beyond histone acetylation that may predict for response, and exploration of drug combinations using DACi that may be effective in advanced CRPC.
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